Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern ...

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

GLP-1 modulators, formally known as glucagon-like peptide-1 receptor agonists, function by enhancing insulin secretion, ...